Company Valuation: Harvard Bioscience, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 287.7 115.4 228.4 92.03 29.81 42.94 - -
Change - -59.89% 97.92% -59.7% -67.6% 44.03% - -
Enterprise Value (EV) 287.7 115.4 228.4 92.03 29.81 42.94 42.94 42.94
Change - -59.89% 97.92% -59.7% -67.6% 44.03% 0% 0%
P/E -705x -12x -66.9x -7.54x -0.52x -4.31x -16.1x 21.8x
PBR 3.65x 1.64x 3.18x 1.47x 2.16x 8.54x 13.8x -
PEG - -0x 1x -0x -0x 0.1x 0.2x -0x
Capitalization / Revenue 2.42x 1.02x 2.03x 0.98x 0.34x 0.48x 0.45x 0.43x
EV / Revenue 0x 0x 0x 0x 0x 0.48x 0.45x 0.43x
EV / EBITDA 0x 0x 0x 0x 0x 5.37x 4.57x -
EV / EBIT 0x 0x 0x 0x 0x 7.16x 4.77x -
EV / FCF 0x -0x 0x -0x 0x -12.6x 22.7x 5.22x
FCF Yield 0.02% -0.38% 5.36% -1.31% 18.3% -7.92% 4.4% 19.2%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.1 -2.3 -0.8 -2.8 -12.8 -2.177 -0.5833 0.43
Distribution rate - - - - - - - -
Net sales 1 118.9 113.3 112.2 94.14 86.55 90.09 94.8 101
EBITDA 1 18.5 10.84 14.55 7.196 8.081 8 9.4 -
EBIT 1 16.72 9.497 13.11 5.294 6.163 6 9 -
Net income 1 -0.288 -9.516 -3.415 -12.4 -56.7 -9.915 -2.765 2.335
Net Debt - - - - - - - -
Reference price 2 70.500 27.700 53.500 21.100 6.688 9.390 9.390 9.390
Nbr of stocks (in thousands) 4,081 4,166 4,269 4,362 4,458 4,573 - -
Announcement Date 08/03/22 09/03/23 07/03/24 12/03/25 12/03/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
-4.31x - - - 42.75M
35.85x6.11x23.34x0.26% 259B
37.05x7.03x22x0.62% 164B
51.3x12.39x26.59x-.--% 154B
18.11x3.57x11.61x-.--% 64.27B
46.2x8.53x26.92x-.--% 61.61B
21.52x2.56x12.9x2.35% 53.94B
33.9x6.72x22.81x0.59% 49.04B
46.16x11.32x24.94x-.--% 48.82B
133.27x7.6x23.09x-.--% 45.24B
Average 41.90x 7.31x 21.58x 0.42% 90B
Weighted average by Cap. 42.64x 7.51x 22.48x 0.36%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Harvard Bioscience, Inc.

Historical PBR trend

Valuation ratios - PBR - Harvard Bioscience, Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Harvard Bioscience, Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Harvard Bioscience, Inc.

  1. Stock Market
  2. Stocks
  3. HBIO Stock
  4. Valuation Harvard Bioscience, Inc.